Ricevi le ultime notizie sulle azioni Century Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di IPSC

Ultime notizie per

CENTURY THERAPEUTICS INC

Century Therapeutics

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Century Therapeutics, Inc. - Common Stock

Century Therapeutics Inc

News

Press Releases

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Clear Street Launches Healthcare & Biotechnology Equity Research

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Earnings

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

Health Care

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

IPSC

JANX

MLTX

NUVB

PTGX

YMAB

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Evaxion

FibroGen

Generation Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

RenovoRx

Senti Biosciences

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Century Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO